"PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Article

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

Hematological Oncology (2021)

C. Carlo-Stella, Humanitas University
Y. Linhares, Baptist Health
M. D. Gandhi, Virginia Cancer Specialists, Medical Oncology Gainesville USA
M. Chung, The Oncology Institute of Hope and Innovation Hematology/Oncology Downey USA
H. Adamis, ADC Therapeutics SA Clinical Development Epalinges Switzerland
D. Ungar, ADC Therapeutics America, Inc Clinical Development Murray Hill USA
M. Hamadani, Medical College of Wisconsin

Link

Disciplines

Publication Date

June 17, 2021

DOI

10.1002/HON.163_2880

Citation Information

C. Carlo-Stella, Y. Linhares, M. D. Gandhi, M. Chung, et al.. "PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5" Hematological Oncology Vol. 39 (2021)
Available at: http://works.bepress.com/yuliya-linhares/36/